在高血压患者中，戊巴比妥与阿普洛尔联合治疗期间，阿普洛尔的血浆浓度降低及其临床效应。
Decreased plasma concentrations and clinical effects of alprenolol during combined treatment with pentobarbitone in hypertension.
作者信息
Seideman P, Borg K O, Haglund K, Von Bahr C
出版信息
Br J Clin Pharmacol. 1987 Mar;23(3):267-71. doi: 10.1111/j.1365-2125.1987.tb03044.x.
The antihypertensive effect of alprenolol has been studied before, during and after additional pentobarbitone treatment. The combined alprenolol-pentobarbitone treatment significantly decreased alprenolol levels by 59% and 4-hydroxyalprenolol by 24%. The effect was significant after three doses and declined over 4-5 days after pentobarbitone withdrawal. The decreased alprenolol plasma levels were associated with increased pulse rate (6%), and systolic (8%) and diastolic (9%) blood pressure. The inhibition of exercise tachycardia by alprenolol was reduced by 18% at the end of pentobarbitone treatment compared to initial monotherapy with alprenolol. The interaction is probably clinically important in those patients with hypertension and angina pectoris that are treated with barbiturates and alprenolol.
已对阿普洛尔在额外戊巴比妥治疗前、治疗期间及治疗后的降压效果进行了研究。阿普洛尔与戊巴比妥联合治疗使阿普洛尔水平显著降低了59%，4-羟基阿普洛尔降低了24%。该效应在三次给药后显著，且在戊巴比妥停药后4 - 5天内逐渐减弱。阿普洛尔血浆水平降低与心率增加（6%）、收缩压（8%）和舒张压（9%）升高有关。与最初单独使用阿普洛尔治疗相比，在戊巴比妥治疗结束时，阿普洛尔对运动性心动过速的抑制作用降低了18%。这种相互作用在接受巴比妥类药物和阿普洛尔治疗的高血压和心绞痛患者中可能具有重要的临床意义。
Zotero 插件